Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Defining the first bona fide cell model for SMARCA4-deficient, undifferentiated tumor.

The Journal of pathology - 1 Sept 2023

Arenas Alberto M, Ruiz-Jiménez José Manuel, López-Hidalgo Javier L, Sanjuán-Hidalgo Juan, Medina Pedro P

Abstract excerpt

The World Health Organization's tumor classification guidelines are frequently updated and renewed as knowledge of cancer biology advances. For instance, in 2021, a novel lung tumor subtype named SMARCA4-deficient, undifferentiated tumor (SMARCA4-dUT, code 8044/3) was included. To date, there is no defined cell model for SMARCA4-dUT that could be used to help thoracic clinicians and researchers in the study of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Lung Neoplasms

Share to Mutation

Share to Rhabdoid Tumor

Source

Identifiers

PMID: 37352131
DOI: 10.1002/path.6141

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Defining the first bona fide cell model for SMARCA4-deficient, undifferentiated tumor.PMID 37352131Read ↗

[Clinical characteristics and prognostic analysis of thoracic SMARCA4-deficient undifferentiated tumor].Semantic proximity Read ↗

Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods.Semantic proximity Read ↗

Establishment and characterization of TRI-LC21: a novel patient-derived cell line of SMARCA4-deficient undifferentiated thoracic tumor.Semantic proximity Read ↗

Clinicopathological characteristics and treatment outcomes of advanced SMARCA4-deficient thoracic tumors.Semantic proximity Read ↗

[Clinicopathological features of SMARCA4-deficient lung adenocarcinoma: a study of 42 cases].Semantic proximity Read ↗

SMARCA4-deficient thoracic malignancies with small cell lung cancer-like features: A clinicopathological and molecular study of a heterogeneous group.Semantic proximity Read ↗

[Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].Semantic proximity Read ↗

Perspectives and Issues in the Assessment of SMARCA4 Deficiency in the Management of Lung Cancer Patients.Semantic proximity Read ↗

Treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go.Semantic proximity Read ↗

Molecular, clinicopathological characteristics and surgical results of resectable SMARCA4- deficent thoracic tumorsSemantic proximity Read ↗

[Clinicopathological analysis of SMARCA4-deficient tumors of digestive system origin].Semantic proximity Read ↗

Clinical features and prognostic biomarkers of patients with the rare SMACRA4 gene mutation in non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.